{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:46:06Z","timestamp":1767033966001,"version":"build-2065373602"},"reference-count":125,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Bladder oversensitivity arises from several different conditions involving the bladder, bladder outlet, systemic or central nervous system diseases. Increase of the bladder sensation results from activation of the sensory receptors in the urothelial cells or suburothelial tissues. Medical treatment targeting the overactive bladder (OAB) or interstitial cystitis (IC) might relieve oversensitive bladder symptoms (frequency, urgency and pain) in a portion of patients, but a certain percentage of patients still need active management. Botulinum toxin A (BoNT-A) has been demonstrated to have anti-inflammatory and antinociceptive effects in bladder sensory disorders and has been shown effective in the reduction of bladder oversensitivity and the increase of functional bladder capacity. For patients with OAB, urgency and urinary incontinence improved, while in patients with IC, bladder pain could be relieved in association with reduction of bladder oversensitivity after BoNT-A intravesical injection. Histological evidence has confirmed the therapeutic mechanism and clinical efficacy of intravesical BoNT-A injection on patients with OAB or IC. Bladder oversensitivity can also be relieved with the instillation of liposome encapsulated BoNT-A or low energy show waves (LESWs), which enable the BoNT-A molecule to penetrate into the urothelium and suburothelial space without affecting the detrusor contractility. Liposome encapsulated BoNT-A or combined LESWs and BoNT-A instillation might be future treatment alternatives for bladder oversensitivity in sensory bladder disorders.<\/jats:p>","DOI":"10.3390\/toxins12030166","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T07:15:26Z","timestamp":1583738126000},"page":"166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders\u2014From Bench to Bedside"],"prefix":"10.3390","volume":"12","author":[{"given":"Yuan-Hong","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan"},{"name":"Department of Urology, Buddhist Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Ru","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Hualien Tzu Chi General Hospital, Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan"},{"name":"Department of Urology, Buddhist Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/luts.12262","article-title":"Pathophysiology of refractory overactive bladder","volume":"11","author":"Chen","year":"2019","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1464-410X.2006.06068.x","article-title":"Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol. Urodyn."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1464-410X.2005.05406.x","article-title":"Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract","volume":"95","author":"Engstrom","year":"2005","journal-title":"BJU Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0090-4295(03)00009-8","article-title":"Estimated economic costs of overactive bladder in the United States","volume":"61","author":"Hu","year":"2003","journal-title":"Urology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eururo.2003.08.015","article-title":"Lower urinary tract symptoms and male sexual dysfunction: The Multinational Survey of the Ageing Male (MSAM-7)","volume":"44","author":"Rosen","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000030497","article-title":"Pathophysiology of lower urinary tract symptoms in aged men without bladder outlet obstruction","volume":"64","author":"Kuo","year":"2000","journal-title":"Urol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study","volume":"87","author":"Milson","year":"2001","journal-title":"BJU Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study","volume":"11","author":"Chuang","year":"2019","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2005.04.026","article-title":"Prevalence of the overactive bladder syndrome by applying the International Continence Society definition","volume":"48","author":"Temml","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03008880410015165","article-title":"Role of the urothelium in bladder function","volume":"215","author":"Birder","year":"2004","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.urols.2016.08.004","article-title":"Urothelial dysfunction and sensory protein expressions in patients with urological or systemic diseases and hypersensitive bladder","volume":"28","author":"Ong","year":"2017","journal-title":"Urol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1464-410X.2003.04722.x","article-title":"Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment","volume":"93","author":"Brady","year":"2004","journal-title":"BJU Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2003.12.017","article-title":"P2X3-immunoreactive nerve fibers in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX)","volume":"46","author":"Brady","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_15","first-page":"37","article-title":"Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and indiopathic unstable human urinary bladder","volume":"77","author":"Smet","year":"1997","journal-title":"Lab. Invest."},{"key":"ref_16","first-page":"456","article-title":"Sensory fibers immunoreactive to the vanilloid receptor protein: Distribution in the urinary bladder","volume":"19","author":"Cruz","year":"2000","journal-title":"Neurourol. Urodyn."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0090-4295(97)00587-6","article-title":"A neurological basis for the overactive bladder","volume":"50","year":"1997","journal-title":"Urology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/jnnp.57.2.169","article-title":"Intravesical capsaicin for treatment of detrusor hyperreflexia","volume":"57","author":"Fowler","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/01.ju.0000081652.31524.27","article-title":"Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions","volume":"170","author":"Kuo","year":"2003","journal-title":"J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(05)63330-2","article-title":"Suppression of bladder hyperreflexia by intravesical resiniferatoxin","volume":"350","author":"Cruz","year":"1997","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.neuint.2004.06.001","article-title":"Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury","volume":"45","author":"Khera","year":"2004","journal-title":"Neurochem. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0306-4522(01)00496-1","article-title":"Vanilloid receptor 1 expression in the rat urinary tract","volume":"109","author":"Avelino","year":"2002","journal-title":"Neuroscience"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1046\/j.1464-410x.2001.02190.x","article-title":"Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder","volume":"87","author":"Yiangou","year":"2001","journal-title":"BJU Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13396","DOI":"10.1073\/pnas.231243698","article-title":"Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells","volume":"98","author":"Birder","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1152\/physrev.00030.2012","article-title":"Urothelial signaling","volume":"93","author":"Birder","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0165-1838(94)90071-X","article-title":"Distribution of NADPH- diaphorase-positive nerves supplying the human urinary bladder","volume":"47","author":"Smet","year":"1994","journal-title":"J. Autonom. Nerv. Syst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/003655999750042187","article-title":"Activation of pelvic afferent nerves from the rat bladder during filling","volume":"201","author":"Morrison","year":"1999","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF01181533","article-title":"The structural relations between nerve fibers and muscle cells in the urinary bladder of the rat","volume":"24","author":"Gabella","year":"1995","journal-title":"J. Neurocytol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Abbasian, B., Shair, A., O\u2019Gorman, D.B., Pena-Diaz, A.M., Brennan, L., Engelbrecht, K., Koenig, D.W., Reid, G., and Burton, J.P. (2019). Potential Role of Extracellular ATP Released by Bacteria in Bladder Infection and Contractility. mSphere, 4.","DOI":"10.1128\/mSphere.00439-19"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/jcmm.12375","article-title":"Telocytes subtypes in human urinary bladder","volume":"18","author":"Vannucchi","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1464-410X.2003.03802.x","article-title":"The role of the human bladder lamina propria myofibroblasts","volume":"91","author":"Wiseman","year":"2003","journal-title":"BJU Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1464-410X.2002.02834.x","article-title":"Gap junctions and connexin expression in human suburothelial interstitial cells","volume":"90","author":"Sui","year":"2002","journal-title":"BJU Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2003.11.003","article-title":"Management of detrusor dysfunction in the elderly: Changes in acetylcholine and adenosine triphosphaterelease during ageing","volume":"63","author":"Yoshida","year":"2004","journal-title":"Urology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00210-006-0073-2","article-title":"TRPVI (vanilloid receptor) in the urinary tract: Expression, function and clinical applications. Naunyn. Schmiedebergs","volume":"373","author":"Avelino","year":"2006","journal-title":"Arch. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E136e41","DOI":"10.1111\/j.1464-410X.2010.09911.x","article-title":"Higher level of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis\/painful bladder syndrome","volume":"108","author":"Shie","year":"2011","journal-title":"BJU Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.tcmj.2012.05.008","article-title":"Pathologic mechanism of the therapeutic effect of botulinum toxin A on interstitial cystitis and painful bladder syndrome","volume":"24","author":"Shie","year":"2012","journal-title":"Tzu. Chi. Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"484.e7","DOI":"10.1016\/j.urology.2011.09.049","article-title":"Increased cell apoptosis of the urothelium is mediated by inflammation in interstitial cystitis\/painful bladder syndrome","volume":"79","author":"Shie","year":"2012","journal-title":"Urology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.eururo.2008.02.037","article-title":"Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity","volume":"53","author":"Apostolidis","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1757-5672.2010.00065.x","article-title":"Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency symptoms","volume":"2","author":"Kuo","year":"2010","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.urology.2008.01.069","article-title":"Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment","volume":"72","author":"Liu","year":"2008","journal-title":"Urology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1464-410X.1997.00097.x","article-title":"Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis","volume":"79","author":"Lowe","year":"1997","journal-title":"Br. J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1016-3190(09)60020-3","article-title":"Pathophysiology of urothelial dysfunction in patients with interstitial cystitis\/ bladder pain syndrome: Increased apoptosis and decreased junctional protein expression in the urothelium due to suburothelial inflammation","volume":"21","author":"Shie","year":"2009","journal-title":"Tzu. Chi. Med. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4155\/cli.12.108","article-title":"Novel treatment of interstitial cystitis\/bladder pain syndrome based on pathophysiology","volume":"2","author":"Kuo","year":"2012","journal-title":"Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/nau.20482","article-title":"Defining overactive bladder as hypersensitivity","volume":"26","author":"Yamaguchi","year":"2007","journal-title":"Neurourol. Urodyn."},{"key":"ref_45","first-page":"16","article-title":"Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction","volume":"212","author":"Simpson","year":"1980","journal-title":"J. Pharmaco.l Exp. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eururo.2009.12.022","article-title":"Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder","volume":"57","author":"Coelho","year":"2010","journal-title":"Eur Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","article-title":"Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions","volume":"8","author":"Aoki","year":"2001","journal-title":"Eur. J. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.eururo.2012.01.046","article-title":"Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action","volume":"61","author":"Coelho","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/nau.22508","article-title":"Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium","volume":"34","author":"Barrick","year":"2015","journal-title":"Neurourol. Urodyn."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of Botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/nau.20105","article-title":"Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?","volume":"24","author":"Kessler","year":"2005","journal-title":"Neurourol. Urodyn."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.urology.2005.02.002","article-title":"Clinical effects of suburothelial injection of botulinum A toxin in patients with non-neurogenic detrusor overactivity refractory to anticholinergics","volume":"66","author":"Kuo","year":"2005","journal-title":"Urology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","article-title":"Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents","volume":"63","author":"Kuo","year":"2004","journal-title":"Urology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"984989","DOI":"10.1097\/01.ju.0000169480.43557.31","article-title":"A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin","volume":"174","author":"Popat","year":"2005","journal-title":"J. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1464-410X.2005.05725.x","article-title":"A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity","volume":"96","author":"Rajkumar","year":"2005","journal-title":"BJU Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ajog.2004.11.052","article-title":"Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study","volume":"192","author":"Werner","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/nau.21132","article-title":"Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxinA injection for idiopathic detrusor overactivity","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.urology.2007.04.038","article-title":"Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis","volume":"70","author":"Liu","year":"2007","journal-title":"Urology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","article-title":"Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection","volume":"56","author":"Liu","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.juro.2008.01.146","article-title":"Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder","volume":"179","author":"Liu","year":"2008","journal-title":"J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1464-410X.2009.08675.x","article-title":"Urinary nerve growth factor level is increased in patients with interstitial cystitis\/painful bladder syndrome and decreased in responders to treatment","volume":"104","author":"Liu","year":"2009","journal-title":"BJU Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eururo.2008.05.007","article-title":"Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats","volume":"56","author":"Chuang","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1464-410X.2006.06677.x","article-title":"Overactive bladder syndrome in older people","volume":"99","author":"Wagg","year":"2007","journal-title":"BJU Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2009.01.007","article-title":"A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women","volume":"55","author":"Wennberg","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1464-410X.2008.07493.x","article-title":"The concept of neurogenic inflammation","volume":"101","author":"Geppetti","year":"2008","journal-title":"BJU Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/S0022-5347(05)64369-8","article-title":"Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats","volume":"168","author":"Seki","year":"2002","journal-title":"J. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0022-5347(05)66587-1","article-title":"The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor","volume":"165","author":"Chuang","year":"2001","journal-title":"J. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.eururo.2009.01.032","article-title":"Overactive bladder is a dynamic syndrome","volume":"55","author":"Kuo","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.juro.2010.02.009","article-title":"Outcomes of intravesical botulinum toxin for idiopathic overactive bladder syndromes: A systemic review of the literature","volume":"183","author":"Anger","year":"2010","journal-title":"J. Urol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo-controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double-blind, placebo-controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline Amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J. Urol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"European Association of Urology. EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"62","author":"Lucas","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","article-title":"Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2005.06.021","article-title":"Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: Objective outcome and patient satisfaction","volume":"48","author":"Weiss","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.urology.2004.08.016","article-title":"Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra","volume":"65","author":"Smith","year":"2005","journal-title":"Urology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006","journal-title":"J. Urol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.urology.2006.05.054","article-title":"Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?","volume":"68","author":"Kuo","year":"2006","journal-title":"Urology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","article-title":"Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux","volume":"177","author":"Karsenty","year":"2007","journal-title":"J. Urol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J. Urol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin a versus placebo for refractory detrusor overactivity in women: A randomised blinded placebo-controlled trial of 240 women (the RELAX study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: A multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J. Urol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Lee, C.L., and Kuo, H.C. (2016). Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility. Toxins, 8.","DOI":"10.3390\/toxins8030082"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/nau.23286","article-title":"Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population","volume":"37","author":"Onem","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","article-title":"Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain response in rats","volume":"172","author":"Chuang","year":"2004","journal-title":"J. Urol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000087173","article-title":"Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis","volume":"75","author":"Kuo","year":"2005","journal-title":"Urol. Int."},{"key":"ref_97","first-page":"414","article-title":"Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model","volume":"20","author":"Cui","year":"2000","journal-title":"Cephalalgia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","article-title":"Botulinum toxin a has antinociceptive effects in treating interstitial cystitis","volume":"64","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2005.12.002","article-title":"Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study","volume":"49","author":"Giannantoni","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.juro.2007.10.032","article-title":"Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup","volume":"179","author":"Giannantoni","year":"2008","journal-title":"J. Urol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J. Urol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/156720110790396463","article-title":"Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrom+e","volume":"7","author":"Giannantoni","year":"2010","journal-title":"Curr. Drug Deliv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2010.02.031","article-title":"Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome\/interstitial cystitis","volume":"58","author":"Pinto","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_105","first-page":"197","article-title":"Intravesical OnabotulinumtoxinA Injections for Refractory Painful Bladder Syndrome","volume":"15","author":"Chung","year":"2012","journal-title":"Pain Physician"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1464-410X.2012.11466.x","article-title":"Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis\/bladder pain syndrome","volume":"111","author":"Shie","year":"2013","journal-title":"BJU Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.36076\/ppj.2013\/16\/E15","article-title":"Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome","volume":"16","author":"Kuo","year":"2013","journal-title":"Pain Physician"},{"key":"ref_108","first-page":"109","article-title":"Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis","volume":"16","author":"Lee","year":"2013","journal-title":"Pain Physician"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.urology.2014.01.018","article-title":"Ulcerative and nonulcerative forms of bladder pain syndrome\/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A","volume":"83","author":"Pinto","year":"2014","journal-title":"Urology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.12659\/MSM.897350","article-title":"Intravesical Botulinum Toxin A Injections for Bladder Pain Syndrome\/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled Studies","volume":"22","author":"Wang","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","article-title":"Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Kuo","year":"2016","journal-title":"Neurourol. Urodyn."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.juro.2017.10.018","article-title":"Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome\/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial","volume":"199","author":"Pinto","year":"2018","journal-title":"J. Urol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kuo, Y.C., and Kuo, H.C. (2016). Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?. Toxins, 8.","DOI":"10.3390\/toxins8030075"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1742-1241.2011.02663.x","article-title":"The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: A randomised double-blind placebo-controlled trial","volume":"65","author":"Dowson","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0090-4295(02)02281-1","article-title":"Intravesical liposomes administration: A novel treatment for hyperactive bladder in the rat","volume":"61","author":"Fraser","year":"2003","journal-title":"Urology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","article-title":"Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes","volume":"182","author":"Chuang","year":"2009","journal-title":"J. Urol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: A single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","article-title":"Bladder instillation of Liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: A prospective, multicenter, double-blind randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J. Urol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.juro.2017.02.021","article-title":"A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis\/bladder pain syndrome","volume":"198","author":"Chuang","year":"2017","journal-title":"J. Urol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4111\/icu.2019.60.5.359","article-title":"Treatment with low-energy shock wave alleviates pain in an animal model of uroplakin 3A-induced autoimmune interstitial cystitis\/painful bladder syndrome","volume":"60","author":"Li","year":"2019","journal-title":"Investig. Clin. Urol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/nau.23141","article-title":"Effects of low energy shock wave therapy on inflammatory moleculars, bladder pain, and bladder function in a rat cystitis model","volume":"36","author":"Wang","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.juro.2015.12.078","article-title":"Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves","volume":"196","author":"Chuang","year":"2016","journal-title":"J. Urol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/2090598X.2019.1605676","article-title":"Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: A preliminary clinical study","volume":"17","author":"Nageib","year":"2019","journal-title":"Arab. J. Urol."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/3\/166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:05:22Z","timestamp":1760173522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/3\/166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":125,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["toxins12030166"],"URL":"https:\/\/doi.org\/10.3390\/toxins12030166","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}